Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand - sprookjes - yvandenbroek - TriplyDB

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

http://www.wikidata.org/entity/Q24653311

about

Interleukin-32 promotes osteoclast differentiation but not osteoclast activation Emerging Functions of RANKL in Lymphoid Tissues TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation A novel zinc finger protein that inhibits osteoclastogenesis and the function of tumor necrosis factor receptor-associated factor 6 Role of the A20-TRAF6 axis in lipopolysaccharide-mediated osteoclastogenesis FLRG, a new ADAM12-associated protein, modulates osteoclast differentiation Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6 RANK is essential for osteoclast and lymph node development CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation Exposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL Bone loss. Factors that regulate osteoclast differentiation: an update.The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption.Anti-cytokine therapy in chronic destructive arthritis Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis.Ubc13: the Lys63 ubiquitin chain building machine Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease RANK-RANKL signalling in cancer The Modulatory Effects of Mesenchymal Stem Cells on Osteoclastogenesis Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics Use of Animal Models in Understanding Cancer-induced Bone Pain Bone health and associated metabolic complications in neuromuscular diseases Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo The regulation of cathepsin K gene expression Physical and functional association of c-Src and adhesion and degranulation promoting adaptor protein (ADAP) in osteoclastogenesis in vitro Key roles of the OPG-RANK-RANKL system in bone oncology NF-kappaB-related genetic diseases RANKL/RANK-beyond bones Role of TNF alpha and PLF in bone remodeling in a rat model of repetitive reaching and grasping Mechanisms of action of therapeutic antibodies for cancer TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling An inducible, ligand-independent receptor activator of NF-κB gene to control osteoclast differentiation from monocytic precursors Arctigenin inhibits osteoclast differentiation and function by suppressing both calcineurin-dependent and osteoblastic cell-dependent NFATc1 pathways Targeting bone remodeling by isoflavone and 3,3'-diindolylmethane in the context of prostate cancer bone metastasis Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies Osteoclast differentiation and activation RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro

P2860

5dba1d9545f9dd50bd5e0b4f23c6d58107256b6c 85c4bcb17c9515488f4e6c0cc6032bfe56afee84 c8e58853cb9941bcc4cc966a4fa25de1a5d7a098

P248

Q21092154-00780859-1EB8-4A4B-848D-92C75DFBF29F Q21131222-CCCD95FA-C3FA-4FBF-9B4F-B46B17A9165C Q22254448-BAFCBE93-AB1E-48C5-B593-C183A0CAFACE Q24292059-273CF3D7-8BE5-4DB8-9211-F9F3E15802F6 Q24311417-6BD4B63C-2227-4E70-B0B7-DAF6F31347A7 Q24318438-9A707F27-6487-4C56-91EF-6DA4C585B6AB Q24537518-269CD1DD-7C58-4D38-9E3B-B1CDF7F7018F Q24598872-201E2CE2-B286-46CC-A755-33687F243FCD Q24609211-B88EB2B7-D654-40E2-A690-454472E75244 Q24673624-DA9F5375-5329-4D12-80B9-A509AE35D5E5 Q24681552-340D32C9-F100-4B3E-A4F3-7566717F48D7 Q24796088-9EC6F688-22C8-4870-AF23-444FC0FBAB1F Q24799036-51414188-629A-4C7C-BDAB-4CD4982B9556 Q24805142-66900F39-C174-4CD0-ACFA-B5209E0DC6BE Q24805207-B4B55A2A-363B-428E-8E57-FF4860DB09BA Q24805245-27885587-EEBB-48E7-9B89-6A504D899319 Q24806847-E14B8123-3B81-4515-9194-AB8D70A9EC0E Q26739716-C0A56503-1A27-46FE-820B-C0B87679831B Q26747224-85529753-73C9-43FE-B988-6880F7BEC753 Q26747442-CA3D3BB1-00DF-466B-9B0C-76497D3A9AEA Q26773017-F33C4D88-B770-46C8-935D-05AFB3585C8F Q26773613-1E4D99A6-4934-4CBA-95D1-A9DE90D0483C Q26785501-2694E376-662C-4C2E-9692-A2BEE2496145 Q27025688-2F532B0C-E075-41B7-ADE4-CC6D3FE4F158 Q28141482-AA2C5FB7-D554-4E4C-9D9A-D1B7DCFE3DC4 Q28191731-00796F01-7CBD-4402-A939-6196A54955D7 Q28251189-DFE04656-33C1-47EE-A666-7F08984B8EDC Q28261795-5A796D73-A8C6-483E-82BC-26D0ADC9D58C Q28287394-D235F48D-A2FC-452C-9171-9AE145225F2D Q28290224-8027A559-D5CB-49B6-881A-F6C5D0A169DB Q28308042-A7149D0C-4DF3-4CA4-B008-A40C544BFF27 Q28384638-D406CD6D-EDC0-438E-91FE-18588846A37C Q28385366-905609D7-A297-44FB-9B69-D191CE328D82 Q28513445-37A62922-250C-4324-B621-4DEA9214E209 Q28538066-CFF3F3CF-9923-4E82-AB2B-DF6CBB6DB884 Q28538824-254BC752-38AB-4480-ADC2-9601FC0EB602 Q28731449-7FAB5F30-19AA-44EC-9EB1-135E29114AE4 Q28749299-30E98A4A-EC62-45C0-AAB5-58FF7106C59D Q29547556-943F0E6F-4321-428A-8635-E3864CE496CC Q30419245-A9F7438E-D908-439D-9C2B-0CF0B6223780

P2860

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

http://www.wikidata.org/entity/Q24653311

description

1999 nî lūn-bûn

@nan

1999 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի մարտին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Tumor necrosis factor receptor ...... uced by osteoprotegerin ligand

@ast

Tumor necrosis factor receptor ...... uced by osteoprotegerin ligand

@en

Tumor necrosis factor receptor ...... uced by osteoprotegerin ligand

@nl

type

label

Tumor necrosis factor receptor ...... uced by osteoprotegerin ligand

@ast

Tumor necrosis factor receptor ...... uced by osteoprotegerin ligand

@en

Tumor necrosis factor receptor ...... uced by osteoprotegerin ligand

@nl

prefLabel

Tumor necrosis factor receptor ...... uced by osteoprotegerin ligand

@ast

Tumor necrosis factor receptor ...... uced by osteoprotegerin ligand

@en

Tumor necrosis factor receptor ...... uced by osteoprotegerin ligand

@nl

P1433

Q24653311-0C45425D-7267-4118-84B9-11CAD93E7673

P1476

Q24653311-E66764A2-1D47-4C44-8B9E-50114927B728

P2093

Q24653311-26D39997-6A44-4B92-AB50-F78175F4CAA4

Q24653311-2C04DAE3-41B6-42D4-9C7D-D07022239E82

Q24653311-2C4A0D95-E048-496A-9806-10809CA6A215

Q24653311-377105EB-5CA4-43E1-8571-65F9458D295B

Q24653311-4497B279-D156-44C8-B6A6-4FE1D194753E

Q24653311-506B8387-D998-4E45-9F62-2D4DCC133D6F

Q24653311-5C24E093-A90A-463B-A4E7-2D3051391CD7

Q24653311-7B41F919-8C34-4303-B80B-6D37EA7DDC9E

Q24653311-7D42EC17-6E25-4B2D-B76F-EA5082C88253

Q24653311-8B668A08-0BC6-495E-9DEE-A7A354FB50B3

P2860

Q24653311-02941481-BDF6-426B-B3A6-5026E981EFD6

Q24653311-048625F2-C963-415E-86CD-1BA2E2A95C83

Q24653311-0831B116-BA6F-49EA-9F18-88D0D0B19E21

Q24653311-08F3E112-0890-4728-B4A5-EB1367AB98DE

Q24653311-105C0007-AEF9-416D-9025-22B3DF86B818

Q24653311-3D5CE2CE-496F-4DC2-B53C-61FF1B024807

Q24653311-454E30A1-56B8-4F6C-9836-56126F2E22D1

Q24653311-4BA74B39-4E2C-465C-85D1-518488FF28CB

Q24653311-591EFC71-9D99-4BBE-8617-6BDBCC75787B

Q24653311-63F4A9F3-AA68-4503-9B33-353196B18792

P304

Q24653311-18E8EA80-9767-4AEB-A69D-D7D519398ADC

P31

Q24653311-3991F06D-E6FC-499B-A96F-82157021FDC1

P3181

Q24653311-AE1CBD38-9855-40AA-9F08-0AF0006AE6E5

P356

Q24653311-074D0F4C-97A2-45A6-A0E2-D9181C1FED9F

P407

Q24653311-AD28B5F6-5835-4BF6-BCAB-8FBF5100B96B

P433

Q24653311-9DA4FDC5-EC48-4543-8C46-E7898EC9E414

P478

Q24653311-2F60E9C7-A443-457C-A451-6034E81794F7

P577

Q24653311-F5EFA8A0-5200-458D-BC36-A80E68054581

P5875

Q24653311-3A2F31CD-6790-4E6C-805E-E92EF925E038

P698

Q24653311-0B6EB72D-9C1A-441D-BD30-1789D8785587

P921

Q24653311-97C09676-1FC2-4B0D-B442-D6910703CD62

Q24653311-D5C15DF8-151C-4230-8D33-419C80D67CFB

Q24653311-EAA04718-4AF6-4ADF-884C-A0FBEB6A53DA

P932

Q24653311-F24C0920-0BF9-4B53-98B7-6354DF5187AE

P3181

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Tumor necrosis factor receptor ...... uced by osteoprotegerin ligand

@en

P2093

A Colombero

http://www.w3.org/2001/XMLSchema#string

C Capparelli

http://www.w3.org/2001/XMLSchema#string

C R Dunstan

http://www.w3.org/2001/XMLSchema#string

D L Lacey

http://www.w3.org/2001/XMLSchema#string

E Timms

http://www.w3.org/2001/XMLSchema#string

G Elliott

http://www.w3.org/2001/XMLSchema#string

G Shimamoto

http://www.w3.org/2001/XMLSchema#string

H Hsu

http://www.w3.org/2001/XMLSchema#string

H L Tan

http://www.w3.org/2001/XMLSchema#string

I Sarosi

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

ATAR, a novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase

The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice

P304

3540-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1332915

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.96.7.3540

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P577

1999-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235615809

http://www.w3.org/2001/XMLSchema#string

P698

10097072

http://www.w3.org/2001/XMLSchema#string

P921

Tumor necrosis factor receptor superfamily, member 11a, NFKB activator

TNF receptor-associated factor 2

TNF receptor-associated factor 6

P932

22329

http://www.w3.org/2001/XMLSchema#string